Advertisement

Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x100px
Organisation › Details

OSE Immunotherapeutics S.A.

OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. OSE Pharma’s lead product, Tedopi®, combines 10 “neo-epitopes” directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase III study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients. OSE Pharma is also planning a new Phase II clinical trial in combination with another immunotherapy treatment in NSCLC. Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or “neo- epitopes”, designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. (ISIN : FR0012127173 ; Mnémo : OSE). *

 

Period Start 2014-09-21 existent
Period End 2016-05-31 merged
  Group OSE Immunotherapeutics (Group)
  Today OSE Pharma S.A.
  Predecessor Effimune SAS
Products Industry Memopi® multi-epitope technology
  Industry 2 Tedopi® cancer immunotherapy
Persons Person Poirier, Nicolas (OSE Immunotherapeutics 202210– CEO + CSO before CSO before Effimune + Tcl Pharma)
  Person 2 Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
     
Region Region Nantes
  Country France
  Street 22 boulevard Benoni Goullin
  City 44200 Nantes
  Tel +33-2-2829-1010
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
  Currency EUR
  Profit -5,584,000 (2015-12-31)
  Cash 15,131,000 (2015-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-05-22

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for OSE Immunotherapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px




» top